Evaluation of Chemosensitivity of Human Bone Marrow Stromal Cells - Differences between Common Chemotherapeutic Drugs

Background: Bone marrow stromal cells (BMSCs) are essential for normal hematopoiesis, but also support the growth and survival of malignant hematopoietic cells. There are currently no data available regarding the sensitivity of BMSCs to cytotoxic drugs widely used in the therapy of hematological dis...

Full description

Saved in:
Bibliographic Details
Published inAnticancer research Vol. 26; no. 1A; pp. 347 - 350
Main Authors SCHMIDMAIER, Ralf, BAUMANN, Philipp, EMMERICH, Bertold, MEINHARDT, Gerold
Format Journal Article
LanguageEnglish
Published Attiki International Institute of Anticancer Research 01.01.2006
Subjects
Antimetabolites, Antineoplastic - pharmacology
Antineoplastic Agents - pharmacology
Antineoplastic Agents, Alkylating - pharmacology
Biological and medical sciences
Bone Marrow Cells - cytology
Bone Marrow Cells - drug effects
Busulfan - analogs & derivatives
Busulfan - pharmacology
Cell Line
Cytarabine - pharmacology
Deoxycytidine - analogs & derivatives
Deoxycytidine - pharmacology
Doxorubicin - pharmacology
Humans
Immunodeficiencies. Immunoglobulinopathies
Immunoglobulinopathies
Immunopathology
Medical sciences
Melphalan - pharmacology
Multiple Myeloma - drug therapy
Multiple Myeloma - pathology
Stromal Cells - drug effects
Tumors
U937 Cells
Antineoplastic agent
Human
Immunopathology
Treatment resistance
multiple myeloma
Acute leukemia
Malignant hemopathy
Myeloma
Cancerology
Immunoglobulinopathy
Lymphoproliferative syndrome
Chemosensitivity
Bone marrow
Bone marrow stromal cells
Stromal cell
drug resistance
Online AccessGet full text

Cover

More Information
Summary:Background: Bone marrow stromal cells (BMSCs) are essential for normal hematopoiesis, but also support the growth and survival of malignant hematopoietic cells. There are currently no data available regarding the sensitivity of BMSCs to cytotoxic drugs widely used in the therapy of hematological diseases such as multiple myeloma or acute leukemia. Materials and Methods: The chemosensitivity of the BMSC line HS-5 and of primary BMSCs from patients were evaluated in comparison to NCI-H929 myeloma and U937 leukemia cells. Results: Both HS-5 cells and human BMSCs showed substantial cell death in response to chemotherapy. While alkylating agents (melphalan, treosulfan) and doxorubicin demonstrated marked BMSC toxicity, nucleotide analogs (gemcitabine, cytarabine) induced only limited BMSC apoptosis. Conclusion: Our data suggest that the BMSC toxicity of cytotoxic compounds should be considered in chemotherapeutic regimens.
ISSN:0250-7005
1791-7530